Northern Trust Corp Hepion Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.51 - $10.4 $614 - $12,532	-1,205 Reduced 0.9%	132,059 $67,000
Q2 2022 Aug 12, 2022	SELL	$0.57 - $1.22 $5,095 - $10,906	-8,940 Reduced 6.29%	133,264 $77,000
Q1 2022 May 13, 2022	BUY	$0.93 - $1.29 $1,120 - $1,554	1,205 Added 0.85%	142,204 $184,000
Q4 2021 Feb 08, 2022	SELL	$1.14 - $1.58 $2,769 - $3,837	-2,429 Reduced 1.69%	140,999 $161,000
Q3 2021 Nov 15, 2021	SELL	$1.39 - $2.1 $2,900 - $4,382	-2,087 Reduced 1.43%	143,428 $220,000
Q1 2021 May 12, 2021	BUY	$1.77 - $2.98 $145,340 - $244,696	82,113 Added 129.51%	145,515 $268,000
Q4 2020 Feb 11, 2021	BUY	$1.58 - $3.64 $100,175 - $230,783	63,402 New	63,402 $139,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $35.1M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.